A glimmer of hope for an Alzheimer’s drug? What’s new with DIAN-TU?
This latest data offers a glimmer of hope for gantenerumab. The decrease in protein levels has led the researchers and the pharmaceutical company Roche to now invite the participants to take part in an open-label extension.
Behind the headlines: Is a new Alzheimer’s treatment in sight?
The Pharmaceutical company Biogen plans to file for US marketing approval for aducanumab, an experimental treatment for early Alzheimer’s disease.
Unlocking patient access to new treatments
Innovative treatments can be life-saving or life-enhancing for patients, their families and carers. Research breakthroughs also drive further scientific discovery, leading to the medicines of tomorrow.
In the news: Alzheimer’s drug trial set back
We’re disappointed that Biogen AND Eisai have stopped two phase III trials of Alzheimer’s drug aducanumab. But we’re encouraged by the growing number of new avenues being explored by researchers across the world. Their work has never been more important.
A closer look at a cannabis-based treatment in Alzheimer’s disease.
Thanks to your support, we are now able to fund a new clinical trial to explore whether a cannabis-based treatment could help.
In the news: What next for anti-amyloid Alzheimer’s drugs?
It’s been a long and agonising wait for clinical trial results to show whether a treatment called solanezumab could be the first new drug licenced for Alzheimer’s in over a decade. But today, hopes seem to have faded for the drug after it failed to meet its primary endpoint in another phase III clinical trial.
In the news: Aducanumab – new Alzheimer’s trial results announced
With 850,000 people currently living with dementia in the UK, and this number set to rise to over one million by 2025, urgency is building around dementia research and the hunt for new treatments that could benefit the millions of people around the world living with the condition.
Silver lining for first anti-tau Alzheimer’s treatment in phase III?
Findings were reported today from the first phase III anti-tau drug in people with mild-to-moderate Alzheimer’s. The drug, called LMTM, was being tested in a 15-month double-blind, controlled trial in 891 people.
The latest progress towards new dementia treatments
At the Alzheimer’s Research UK Conference 2016 in Manchester this week we’ve been hearing about some of the latest emerging research from across the UK.
New Year’s Resolution: Get involved in dementia research
It’s that time of year again where we all start to think about what we can do to be better people. I’ve gone for the classics; I’m going to start at the gym, sort my diet out, and sign up to help make breakthroughs possible!